Business Context and Reporting Period
Company: Integer Holdings Corp (ITGR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 28, 2025
Business Overview: Integer is a medical device contract development and manufacturing organization (CDMO) serving cardiac rhythm management, neuromodulation, and cardio/vascular markets. The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Sales | $437,392 | $407,796 |
| Gross Profit | $120,318 | $108,273 |
| Gross Margin | 27.5% | 26.6% |
| Operating Income | $49,552 | $38,701 |
| Operating Margin | 11.3% | 9.5% |
| Net Income (Loss) | $(22,487) | $20,508 |
| Diluted EPS | $(0.66) | $0.59 |
| Operating Cash Flow | $31,276 | $23,239 |
| Cash and Equivalents (End of Period) | $31,711 | $42,156 |
| Total Debt (Net Carrying Amount) | $1,235,204 | $990,153 |
| Working Capital | $495,800 | $443,946 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 7.3% ($29.6M) driven by strong demand in Cardio & Vascular (+16.7%) and contributions from recent acquisitions (Precision and VSi). The "Other Markets" segment declined 37.4% due to the planned exit of the Portable Medical business.
- Profitability Impact: Despite a 28.0% increase in Operating Income, the company reported a Net Loss of $22.5M compared to Net Income of $20.5M in Q1 2024. This reversal was primarily caused by a $46.7M non-cash induced conversion expense recorded in "Other loss, net" related to the exchange of 2028 Convertible Notes.
- Debt Restructuring: The company issued $1.0 billion in 2030 Convertible Notes and used proceeds to exchange $383.7M of 2028 Convertible Notes and pay down senior secured credit facilities. Total debt increased, but the mix shifted toward longer-term fixed-rate instruments.
- Acquisitions: Completed acquisitions of Precision Coating LLC ($153.5M) and VSi Parylene ($24.0M), adding $13.3M in sales during the quarter.
Guidance, Outlook, and Risks
- Convertible Note Conversion Risk: The 2028 Convertible Notes are currently eligible for conversion by holders through June 30, 2025. Management intends to refinance any conversion obligations using the Revolving Credit Facility ($794.7M available capacity). Failure to meet conversion obligations could trigger a default.
- Market Exit: The company continues to wind down the Portable Medical market, with final sales expected in 2025.
- Liquidity: Management believes cash flows, cash on hand, and borrowing capacity are sufficient for the next 12 months. Contractual debt service for the next 12 months is estimated at $32M (interest only), as principal payments have been prepaid.
- Tax Rate Volatility: The effective tax rate for Q1 2025 was (72.8%) due to the non-deductible nature of the induced conversion expense. Future rates may vary based on discrete items and jurisdictional mix.
Investor Verification Checklist
- Induced Conversion Expense: Verify the accounting treatment and tax implications of the $46.7M expense related to the 2028 Note exchange.
- Convertible Note Status: Monitor the trading price of ITGR stock relative to the conversion price of the 2028 Notes to assess the likelihood of further conversions and potential dilution or cash outflows.
- Acquisition Integration: Track the revenue contribution and margin impact of the Precision and VSi acquisitions against the $9.0M in contingent consideration (earn-outs) obligations.
- Debt Covenants: Confirm continued compliance with the Total Net Leverage Ratio (currently ~2.8:1.0) and Interest Coverage Ratio (currently ~8.6:1.0) under the Senior Secured Credit Facilities.
- Portable Medical Exit: Assess the timeline and cost implications of the final exit from the Portable Medical segment in 2025.